Received a Nasdaq notification of non-compliance with the $1.00 minimum bid price requirement. Terminated the HyBryte (synthetic hypericin) development program for cutaneous T-cell lymphoma following a recommendation from the Data Monitoring Committee to halt the FLASH2 trial for futility. Estimated wind-down costs for the HyBryte program are approximately $70,000. Consulting Chief Medical Officer Dr. Richard C. Straube ceased his role effective June 11, 2026, with responsibilities transitioning to Medical Director Dr. Christopher Pullion. The company is evaluating strategic options, including potential mergers and acquisitions, while focusing on its remaining pipeline, specifically dusquetide (SGX945) for Behcet's Disease.